ALLMedicine™ Cholangiocarcinoma Center

Dec 4th, 2021 - Intrahepatic cholangiocarcinoma is a highly lethal malignancy characterized by lymph node metastasis. This study aimed to evaluate the efficacy of indocyanine green fluorescence for visualization of lymphatic drainage and to assess its clinical ap...

Dec 4th, 2021 - Cholangiocarcinoma (CCA) represents the second most common primary liver malignancy after hepatocellular carcinoma and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the ...

Dec 3rd, 2021 - This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esopha...

Dec 3rd, 2021 - Intrahepatic cholangiocarcinoma (iCCA) has previously been considered a contraindication to liver transplantation (LT). However, recent series showed favorable outcomes for LT after neoadjuvant therapy. Our center developed a protocol for neoadjuv...

Dec 3rd, 2021 - Primary liver cancer, mainly comprising hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), remains a major global health problem. Although ICC is clinically different from HCC, their molecular differences are still largely u...

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Jul 15th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Dec 3rd, 2021 - This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esopha...

Dec 3rd, 2021 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellul...

Dec 3rd, 2021 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

Nov 29th, 2021 - The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma wi...

Nov 24th, 2021 - When a patient is not eligible for surgery, chemotherapy with gemcitabine and cisplatin can be considered in advanced biliary tract cancers. However, in the Advanced Biliary Cancer, or ABC-2, trial in patients with pCCA, the efficacy of this regim...

Oct 8th, 2021 - Daniel H. Ahn, DO, consultant, Division of Hematology/Oncology, Department of Internal Medicine, assistant professor of medicine, Mayo Clinic, discusses the increased understanding of cholangiocarcinoma. The field’s understanding of cholangioca...

Oct 6th, 2021 - Gerald S. Falchook, MD, MS Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon, said Gerald S. Falchook, MD, MS, adding that these rare oncogeneic dr...

Oct 6th, 2021 - Nivolumab (Opdivo) followed by treatment with tumor-infiltrating lymphocytes (TILs) was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer (NSCLC), according to data from a phase 1 trial (NCT03...

Oct 6th, 2021 - David Hyman, MD Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion—positive solid tumors, according to updated results for the novel pan-TRK inhibitor published in the New England Journal of Medicine (NEJM).1 Among 55...

Oct 6th, 2021 - We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, faculty from the Florida Society of Clinical Oncology discussed the novel agents that are generating excitement in advanced...